Celltrion has already obtained approval for Remsima from over 50 countries worldwide, including Europe, Canada and Japan.
Just yesterday, Celltrion announced the launch of Remsima in 12 European markets through a partnership with Hospira. Those countries include Austria, Belgium, Denmark, France, Germany, Greece, Italy, Luxembourg, the Netherlands, Spain, Sweden and the UK.
The U.S. may be a ways off.